We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume |
---|---|---|---|---|---|
TVGN | Tevogen Bio Holdings Inc | 1.39 | 0.4055 | 41.19% | 1,403,071 |
NXU | NXU Inc | 0.48 | 0.0686 | 16.67% | 2,112,115 |
ATRA | Atara Biotherapeutics Inc | 0.6021 | 0.0722 | 13.63% | 7,956 |
RGF | Real Good Food Company Inc | 0.50 | 0.0568 | 12.82% | 3,604 |
MIGI | Mawson Infrastructure Group Inc | 1.15 | 0.13 | 12.75% | 27,368 |
ESLA | Estrella Immunopharma Inc | 1.19 | 0.11 | 10.19% | 1,770 |
FAT | FAT Brands Inc | 5.97 | 0.55 | 10.15% | 3,627 |
LEXX | Lexaria Bioscience Corporation | 3.88 | 0.33 | 9.30% | 600 |
WAVD | WaveDancer Inc | 3.25 | 0.27 | 9.06% | 38,920 |
MTEM | Molecular Templates Inc | 1.61 | 0.13 | 8.78% | 2,000 |
VCNX | Vaccinex Inc | 6.20 | 0.45 | 7.83% | 2,023 |
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2024, recent business highlights, and key upcoming milestones for 2024.
Patent, once issued, will provide composition protection through 2040, with potential for additional term extension Annamycin is advancing towards pivotal AML study in 2024 and may qualify for an accelerated approval pathway HOUSTON, May 9, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has received an Issue Notification from the United States Patent and Trademark Office (USPTO) for U.S. Patent number 11,980,634 titled, "Method of Reconstituting Liposomal Annamycin" (the '634 patent') to be issued on May 14, 2024 ...
AEye, Inc. (NASDAQ: LIDR), a global leader in adaptive, high-performance lidar solutions, today announced that the non-binding Letter of Intent (“LOI”) announced in March is with LITEON Technology Corporation and is intended to provide AEye with a customer channel and industrialization partnership. Both companies will work together to supply AEye’s 4Sight™-based lidar products to automotive original equipment manufacturers (“OEMs”) who are focused on safety through automotive Advanced Driver Assistance Systems (“ADAS”). This is a logical collaboration as AEye continues to focus on its unique capital light business model, which leverages automotive Tier 1 partnerships to deliver AEye’s lidar solutions to ...
Translational Study Provides Pre-Clinical Evidence to Support The Design of a Phase 1 Study of the Hemopurifier In Cancer Patients With Solid Tumors Treated With Anti-PD-1 Antibodies SAN DIEGO, May 10, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced positive results from an in vitro binding study of its Hemopurifier® in removing extracellular vesicles (EVs) from plasma. The translational study provides pre-clinical evidence to support Aethlon's planned phase 1 safety, feasibility and dose-finding clinical trials of the Hemopurifier in patients with solid tumors ...
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 60,867.76 | -2,180.70 | -3.46% | 1.19T | 4,586,338,124 |
ETH | Ethereum | 2,906.62 | -129.48 | -4.26% | 348.39B | 1,935,426,583 |
USDT | Tether USD | 0.99975 | -0.00011 | -0.01% | 97.81B | 202,845,148 |
BNB | Binance Coin | 585.85 | -10.46 | -1.75% | 92.38B | 250,597,277 |
SOL | Solana | 146.04 | -6.74 | -4.41% | 64.09B | 1,131,754,330 |
STETH | stETH | 2,905.17 | -129.72 | -4.27% | 28.3B | 4,568,042 |
USDC | USD Coin | 1.00 | 0.00 | 0.00% | 28.07B | 752,934,686 |
XRP | Ripple | 0.5015 | -0.0194 | -3.72% | 27.31B | 300,604,152 |
TONCOIN | Wrapped TON Coin | 6.71 | 0.350065 | 5.51% | 23.33B | 396,725,736 |
DOGE | Dogecoin | 0.14356 | -0.00844 | -5.55% | 20.47B | 357,343,575 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions